Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray

Neurochemical Research

Volumn 27, Issue 10, 2002, Pages 1231-1243

  Mandel, Silvia ^a   Grünblatt, Edna ^a,b   Maor, Gila ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

cDNA microarray; Gene expression; MPTP; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; COMPLEMENTARY DNA; DOPAMINE; GLUTAMIC ACID; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; CONTROLLED STUDY; CORPUS STRIATUM; DNA MICROARRAY; GENE EXPRESSION; INFLAMMATION; MALE; MOUSE; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; DNA, COMPLEMENTARY; DOPAMINE AGENTS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE, SECONDARY; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 0036808013     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020989812576     Document Type: Article

References (67)

1. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:415-455.
2. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K., and Youdim, M. B. H. 1989. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:515-520.
3. Perry, T. L., Yong, V. W., Jones, K., and Wright, J. M. 1986. Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Neurosci. Lett. 70:261-265.
4. Hirsch, E. C. 2000. Glial cells and Parkinson's disease. J. Neurol. 247 (Suppl 2): II58-II62.
5. Chase, T. N. and Oh, J. D. 2000. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23:S86-S91.
6. Uversky, V. N., Li, J., and Fink, A. L. 2001. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276:10737-10744.
7. Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M. P., Ruberg, M., Faucheux, B. A., Agid, Y., and Hirsch, E. C. 1997. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. USA 94:7531-7536.
8. Loopuijt, L. D. and Schmidt, W. J. 1998. The role of NMDA receptors in the slow neuronal degeneration of Parkinson's disease. Amino Acids 14:17-23.
9. Iacopino, A. M. and Christakos, S. 1990. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 87:4078-4082.
10. Nagai, Y., Ueno, S., Saeki, Y., Soga, F., Hirano, M., and Yanagihara, T. 1996. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 46:791-795.
11. Ben-Shachar, D., Eshel, G., Finberg, J. P., and Youdim, M. B. 1991. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1441-1444.
12. Olanow, C. W. 1996. Neurodegeneration and Neuroprotection in Parkinson's Disease. New York, Academic Press.
13. Grunblatt, E., Mandel, S., Berkuzki, T., and Youdim, M. B. H. 1999. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14:612-618.
14. Levites, Y., Weinreb, O., Maor, G., Youdim, M. B. H., and Mandel, S. 2001. Green tea polyphenol (-)- Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78:1073-1082.
15. Youdim, M. B. H., Gassen, M., Gross, A., Mandel, S., and Grunblatt, E. 2000. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. J. Neural. Transm. Suppl:83-96.
16. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D. K., Ischiropoulos, H., and Przedborski, S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22:1763-1771.
17. Klivenyi, P., Andreassen, O. A., Ferrante. R. J., Lancelot, E., Reif, D., and Beal, M. F. 2000. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport 11:1265-1268.
18. Guo, X., Dawson, V. L., and Dawson, T. M. 2001. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur. J. Neurosci. 13: 1683-1693.
19. Maimone, D., Dominici, R., and Grimaldi, L. M. 2001. Pharmacogenomics of neurodegenerative diseases. Eur. J. Pharmacol. 413:11-29.
20. Deleted in proof.
21. Mandel, S., Grunblatt, E., and Youdim, M. B. H. 2000. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: Implications for idiopathic Parkinson's disease. J. Neural. Transm. Suppl. 60:117-124.
22. Grunblatt, E., Mandel, S., Maor, G., and Youdim, M. B. H. 2001. Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. J. Neurochem. 78:1-12.
23. Cochiolo, J. A., Ehsanian, R., and Bruck, D. K. 2000. Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: Evidence of compensatory plasticity in nigrostriatal neurons. J. Neurosci. Res. 59:126-135.
24. Chan, P., Langston, J. W., and Di Monte, D. A. 1993. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. J. Pharmacol. Exp. Ther. 267:1515-1520.
25. Studer, A., Sundstrom, E., Jonsson, G., and Schultz, W. 1988. Acute electrophysiological and neurochemical effects of administration of MPTP in mice. Neuropharmacology 27:923-931.
26. Mori, S., Fujitake, J., Kuno, S., and Sano, Y. 1988. Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3.6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies. Neurosci. Lett. 90:57-62.
27. Garthwaite, J., Garthwaite, G., Palmer, R. M., and Moncada, S. 1989. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur. J. Pharmacol. 172:413-416.
28. Sequeira, S. M., Ambrosio, A. F., Malva, J. O., Carvalho, A. P., and Carvalho, C. M. 1997. Modulation of glutamate release from rat hippocampal synaptosomes by nitric oxide. Nitric Oxide 1:315-329.
29. Carvalho, A. P., Sequeira, S. M., Duarte, C. B., and Carvalho, A. P. 2000. Pages 157-176, in Free Radicals in Brain Pathophysiology (Giuseppe, P., Enrique, C., and Lester, P., eds), Marcel Dekker Inc., New York.
30. Ilic, T. V., Jovanovic, M., Jovicic, A., and Tomovic, M. 1999. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct. Neurol. 14:141-147.
31. Barker, J. E., Heales, S. J., Cassidy, A., Bolanos, J. P., Land, J. M., and Clark, J. B. 1996. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage. Brain Res. 716:118-122.
32. Cassarino, D. S., Fall, C. P., Swerdlow, R. H., Smith, T. S., Halvorsen, E. M., Miller, S. W., Parks, J. P., Parker, W. D., Jr., and Bennett, J. P., Jr. 1997. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362:77-86.
33. Kim-Han, J. S. and Sun, A. Y. 1998. Protection of PC12 cells glutathione peroxidase in L-DOPA induced cytotoxicity. Free Radic. Biol. Med. 25:512-518.
34. Bensadoun, J. C., Mirochnitchenko, O., Inouye, M., Aebischer, P., and Zurn, A. D. 1998. Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice. Eur. J. Neurosci. 10:3231-3236.
35. Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., and Nagatsu, T. 1996. Interleukin (IL)-I beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211:13-16.
36. Mogi, M., Togari, A., Ogawa, M., Ikeguchi, K., Shizuma, N., Fan, D., Nakano, I., and Nagatsu, T. 1998. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1 beta and nerve growth factor in the striatum. Neurosci. Lett. 250:25-28.
37. Bessler, H., Djaldetti, R., Salman, H., Bergman, M., and Djaldetti, M. 1999. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed. Pharmacother. 53:141-145.
38. Lavrovsky, Y., Chatterjee, B., Clark, R. A., and Roy, A. K. 2000. Role of redox-regulated transcription factors in inflammation, aging and age-related diseases. Exp. Gerontol. 35:521-532.
39. Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., and Youdim, M. B. H. 1990. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural. Transm. Park. Dis. Dement. Sect. 2:327-340.
40. Schreck, R., Rieber, P., and Baeuerle, P. A. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10:2247-2258.
41. Crisi, G. M., Santambrogio, L., Hochwald, G. M., Smith, S. R., Carlino, J. A., and Thorbecke, G. J. 1995. Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: Protection by transforming growth factor-beta and interleukin-10. Eur. J. Immunol. 25:3035-3040.
42. Balasingam, V. and Yong, V. W. 1996. Attenuation of astroglial reactivity by interleukin-10. J. Neurosci. 16:2945-2955.
43. Koedel, U., Bernatowicz, A., Frei, K., Fontana, A., and Pfister, H. W. 1996. Systemically (but not intrathecally) administered IL-10 attenuates pathophysiologic alterations in experimental pneumococcal meningitis. J. Immunol. 157:5185-5191.
44. Brewer, K. L., Bethea, J. R., and Yezierski, R. P. 1999. Neuroprotective effects of interleukin-10 following excitotoxic spinal cord injury. Exp. Neurol. 159:484-493.
45. Carboni, S., Melis, F., Pani, L., Hadjiconstantinou, M., and Rossetti, Z. L. 1990. The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+). Neurosci. Lett. 117:129-133.
46. Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., and Snyder, S. H. 1991. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 88:6368-6371.
47. Lei, S. Z., Pan, Z. H., Aggarwal, S. K., Chen, H. S., Hartman, J., Sucher, N. J., and Lipton, S. A. 1992. Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron 8:1087-1099.
48. Lipton, S. A., Choi, Y. B., Pan, Z. H., Lei, S. Z., Chen, H. S., Sucher,. N. J., Loscalzo,. J., Singel, D. J., and Stamler, J. S. 1993. A redox-based mechanism for the neuroprotective and neuro-destructive effects of nitric oxide and related nitroso-compounds. Nature 364:626-632.
49. Fagni, L., Olivier, M., Lafon-Cazal, M., and Bockaert, J. 1995. Involvement of divalent ions in the nitric oxide-induced blockade of N- methyl-D-aspartate receptors in cerebellar granule cells. Mol. Pharmacol. 47:1239-1247.
50. Kroncke, K. D., Fehsel, K., and Kolb-Bachofen, V. 1997. Nitric oxide: Cytotoxicity versus cytoprotection - How, why, when, and where? Nitric Oxide 1:107-120.
51. McShea, A., Wahl, A. F., and Smith, M. A. 1999. Re-entry into the cell cycle: A mechanism for neurodegeneration in Alzheimer disease. Med. Hypotheses 52:525-527.
52. Raina, A. K., Zhu, X., Rottkamp, C. A., Monteiro, M., Takeda, A., and Smith, M. A. 2000. Cyclin' toward dementia: Cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J. Neurosci. Res. 61:128-133.
53. Levites, Y., Amit, T., Youdim, M. B. H., and Mandel, S. 2002. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J. Biol. Chem. 277:30574-30580.
54. Hadjiconstantinou, M., Fitkin, J. G., Dalia, A., and Neff, N. H. 1991. Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurochem. 57:479-482.
55. Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S., and Collins, F. 1993. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons [see comments]. Science 260: 1130-1132.
56. Hunot, S., Bernard, V., Faucheux, B., Boissiere, F., Leguern, E., Brana, C., Gautris, P. Guerin, J., Bloch, B., Agid, Y., and Hirsch, E. C. 1996. Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: A post mortem in situ hybridization study with special reference to Parkinson's disease. J. Neural. Transm. (Budapest) 103:1043-1052.
57. Gash, D. M., Zhang, Z., and Gerhardt, G. 1998. Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. 44:S121-S125.
58. Ishii, T., Yanagawa, T., Yuki, K., Kawane, T., Yoshida, H., and Bannai, S. 1997. Low micromolar levels of hydrogen peroxide and proteasome inhibitors induce the 60-kDa A170 stress protein in murine peritoneal macrophages. Biochem. Biophys. Res. Commun. 232:33-37.
59. Xie, T., Tong, L., Barrett, T., Yuan, J., Hatzidimitriou, G., McCann, U. D., Becker, K. G., Donovan, D. M., and Ricaurte, G. A. 2002. Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 22: 274-283.
60. Cadet, J. L., Jayanthi, S., McCoy, M. T., Vawter, M., and Ladenheim, B. 2001. Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: Evidence from cDNA CDNA array. Synapse 41:40-48.
61. Kumer, S. C. and Vrana, K. E. 1996. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67:443-462.
62. Saporito, M. S., Thomas, B. A., and Scott, R. W. 2000. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75:1200-1208.
63. Gearan, T., Castillo, O. A., and Schwarzschild, M. A. 2001. The parkinsonian neurotoxin, MPP(+) induces phosphorylated c-Jun in dopainergric neurons of mesencephalic cultures. Parkinsonism Relat. Disord. 8:19-22.
64. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism [see comments]. Nature 392: 605-608.
65. Shimura, H., Hattori, N., Kubo, S., Yoshikawa, M., Kitada, T., Matsumine, H., Asakawa, S., Minoshima, S., Yamamura, Y., Shimizu, N., and Mizuno, Y. 1999. Immunohistochemical and subcellular localization of Parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45:668-672.
66. Chen, J. Y., Hsu, P. C., Hsu, I. L., and Yeh, G. C. 2001. Sequential up-regulation of the c-fos, c-jun and bax genes in the cortex,. Striatum and cerebellum induced by a single injection of a low dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice. Neurosci. Lett. 314:49-52.
67. Ara, J., Przedborski, S., Naini, A. B., Jackson-Lewis, V., Trifiletti, R. R., Horwitz, J., and Ischiropoulos, H. 1998. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl. Acad. Sci. USA 95:7659-7663.